Reacciones adversas del imatinib registrados en el departamento de hematología del hospital del clínicas

Abstract

Background:
The imatinib, the first tyrosine kinase protein BCR-ABL inhibitor, is designed
for the treatment of chronic myeloid leukemia (CML)(1). The use of Imatinib
for the treatment of CML is replacing that of the conventional chemotherapy.
Thus, it has been shown that the treatment with Imatinib has different
adverse reactions than that of chemotherapy(2). Compared with chemotherapy,
adverse reactions resulting from prolonged use of Imatinib are diverse
an distinct compared with other agents(3). The study was proposed with the
idea of searching the records of the Hematology Department of the Hospital
de Clinicas for information regarding adverse reactions in patients undergoing
treatment with Imatinib.
Methods: 
Descriptive observational study, retrospective. Non-probabilistic sampling for
convenience. In hematoncologic patients of the Hematology Department of
the Hospital de Clinicas treated with Imatinib since 2001. Variables will be
represented by measures of central tendency.
Results: 
Of 99 patients the 87% (88 patients) presented some adverse reaction during
the treatment with Imatinib. The 57% were men. The age range with more
prevalence was between 41-60 years old (41,4%). The most frecuent adverse
reactions were: anemia (27.27%), cutaneous eruptions (23.23%) and leukopenia
(21.21%). Hematologic reactions being the most frequent (51%).
Conclusion: 
Young and middle age adults were the most affected by these reactions. Of
the adverse reactions attributable to Imatinib, the most frequent between the
patients treated in the Hematology Department of the Hospital de Clinicas
was the anemia.

Received: 04/09/2020. Accepted: 07/11/2020